Six appointees will bring expertise in biotech, pharma, law, science policy, investment and academia

The Board of Overseers, established in 2018 by Scripps Research’s President and CEO Peter Schultz, PhD, amplifies the institute’s advisory network and provides support for philanthropic efforts that ensure critical research is pursued to its fullest extent.

The newest members of the Board of Overseers are:

Stacy Kellner Rosenberg, retired attorney, noted philanthropist and former nonprofit leader who is an ardent supporter of science.

John Hood, PhD, a former research fellow at Scripps Research who has founded or cofounded multiple innovative life science companies including Endeavor Biomedicines, Impact Biomedicines and Samumed.

Nate Dalton, founder of Daybreak Partners, an investment firm focused on the intersection of healthcare and technology; he is also cofounder and former CEO of global asset management company Affiliated Managers Group, where he now serves as senior advisor.

Brian Dovey, a partner at life science venture capital firm Domain Associates, where he has served on the board of more than 35 companies and has been chairman of six.

Sandford (Sandy) Smith, former executive vice president of Genzyme, CEO of two biopharma companies and a board member of multiple publicly traded biotech companies, where he focuses on commercial strategy.

Isy Goldwasser, who transitions from the Board of Directors into a new role as Scripps Research’s inaugural Entrepreneur-in-Residence. Goldwasser is an investor, as well as a cofounder and CEO at biotech companies including Thync and Symyx Technologies.

“More than ever, the world needs innovative science—and a framework that enables great science to be translated efficiently into life-saving medicines.”

-Peter Schultz, PhD
President and CEO, Scripps Research